TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05713162

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptation of the Social Adjustment Enhancement Intervention of the UC Davis MIND Institute (Solomon, 2004).
Description: The social skills intervention program was based on a consented adaptation of the Social Adjustment Enhancement Intervention of the UC Davis MIND Institute (Solomon, 2004). In order to be feasible in a hospital-based service, we adapted the program to 10 sessions. Session structure included initial greeting, free play time, didactic, joke telling, and closing activities. Topics of didactic sessions were related to social competence, such as empathy, talking about feelings, and solving social problems. We also adapted the content of the sessions, including activities proposed by Solomon (2004) but also from other experts in social cognition, such as García-Winner (2000). Each group was comprised by 7-10 participants. Children groups were conducted by a clinical psychologist, a mental health nurse and the support of two master degree students. Adolescent groups were conducted by a psychologist, a psychiatrist and the support of two master degree students.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptation of the Social Adjustment Enhancement Intervention of the UC Davis MIND Institute (Solomon, 2004).
Description: The social skills intervention program was based on a consented adaptation of the Social Adjustment Enhancement Intervention of the UC Davis MIND Institute (Solomon, 2004). In order to be feasible in a hospital-based service, we adapted the program to 10 sessions. Session structure included initial greeting, free play time, didactic, joke telling, and closing activities. Topics of didactic sessions were related to social competence, such as empathy, talking about feelings, and solving social problems. We also adapted the content of the sessions, including activities proposed by Solomon (2004) but also from other experts in social cognition, such as García-Winner (2000). Each group was comprised by 7-10 participants. Children groups were conducted by a clinical psychologist, a mental health nurse and the support of two master degree students. Adolescent groups were conducted by a psychologist, a psychiatrist and the support of two master degree students.
Study: NCT01613963

Intervention type: DRUG
Intervention: Immunosuppressive Agents
Description: Treatment with systemic corticosteroids and/or immunosuppressive agents Treatment with local corticosteroids and other drugs
Study: NCT02698306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Sodium
Description: Diclofenac Sodium
Study: NCT01991145

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood therapy
Description: HLA (Human Leukocyte Antigen) typing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Umbilical Cord Blood therapy
Description: HLA (Human Leukocyte Antigen) typing

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Erythropoietin alfa

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Erythropoietin alfa

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Active rehabilitation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: Active rehabilitation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: Active rehabilitation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rehabilitation
Description: Active rehabilitation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo UCB

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo UCB

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo EPO

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo EPO
Study: NCT02271230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D and fish oil
Description: 2000 IU vitamin D and 1g/d fish oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil (EPA/DHA) alone
Description: 1 g/d fish oil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D alone
Description: 2000 IU vitamin D

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vitamin D placebo and fish oil placebo
Study: NCT02489409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EndostarTM Injection
Description: 210 mg in 279 mL normal saline (NS), continuous pump, d1-d10 (2.5 mL/h)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1.0 m/m2, iv 0.5h, d1, 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1.0 m/m2, iv 0.5h, d1, 8

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Navelbine
Description: 40 mg/d, iv, d1, 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navelbine
Description: 40 mg/d, iv, d1, 8

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platinum
Description: 30 mg/m2, iv 3h, d1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum
Description: 30 mg/m2, iv 3h, d1-3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xeloda Tablets:
Description: 2 000 mg/m2, po, d1-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeloda Tablets:
Description: 2 000 mg/m2, po, d1-14
Study: NCT00020722

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous lymphocytes
Description: Immediately after pheresis, the lymphocytes will be activated with soluble monoclonal anti-CD3 antibody (OKT3) which cross-links the CD3 receptors on T cells and activates T cells.~The time for ATC infusions will vary from patient to patient, but the infusion rate will be based on the rate calculated from the endotoxin level in the cell product. All patients will be observed for at least 1 hr after an infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide, carboplatin, and etoposide (ICE) regimen
Description: Ifosfamide 2,500 mg/m2 given IV daily on day -8, -7, -6, -5, -4, and -3 prior to PBSCT. Ifosfamide 2,500 mg/m2 infused IV over 1 hour (hour 0-1) on days -8 to -3 for a total dose of 15,000 mg/m2.~Mesna will be administered per BMT Standard of Care Guideline at a dose of 25% of the total Ifosfamide dose 30 minutes prior to and then 3, 6, and 9 hours after ifosfamide daily on days -8, -7, -6, -5, -4, and -3 prior to PBSCT for a total dose of 2500 mg/m2.~Carboplatin at a dose of 250 mg/m2 will be given daily on days -8, -7, -6, -5, -4, and -3 prior to PBSCT for a total dose of 1500 mg/m2.~VP-16 (etoposide) at a dose of 200 mg/m2 will be given IV on days -8, -7, -6, -5, -4 and -3. The total dose of VP-16 given prior to PBSCT will be 2,400 mg/m2. VP-16 will be given 200 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Thiotepa, Carboplatin (CTC) or STAMP V (CTC)
Description: Cyclophosphamide will be given at a dose of 2000 mg/m2 in NS IV over one hour daily on days -4, -3, and -2 (total = 6000 mg/m2).~Thiotepa will be given at a dose of 167 mg/m2 in NS IV over one hour daily on days -4, -3, -2 (total = 500 mg/m2) as the preparative regimen followed by PBSCT on day 0.~Carboplatin will be given at a dose of 267 mg/m2 in D5W IV over one hour daily on days -4, -3, and -2.~Mesna will be administered per BMT Standard of Care Guidelines at a dose of 25% of the total cyclophosphamide dose 30 minutes prior to and then 3, 6, and 9 hours after cyclophosphamide daily on days -4, -3, and -2 prior to PBSCT for a total of 2000mg/m2.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Peripheral blood mononuclear cells (PBMC) will be collected by leukapheresis (for generation of ATC) prior to or post G-CSF (16 ug/kg/day) priming for collecting stem cells.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation (PBSCT)
Description: Will be collected either before or after peripheral blood stem cell collection for stem cell transplant.
Study: NCT02121327

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: disease management
Description: disease management program include self management education

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: usual care
Description: usual care group receive regular outpatient treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: usual care group receive regular outpatient treatment
Study: NCT04555005

Intervention type: OTHER
Group type: OTHER
Intervention: Mindfulness based intervention
Description: Mindfulness based intervention for frontline healthcare workers during COVID-19 outbreak
Study: NCT03191071

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: UltraPro
Description: First, procalcitonin will be measured using a rapid point-of-care test. In case of elevated procalcitonin result (≥0.25 µg/L), a lung ultrasound will be performed to look for the presence of a lung infiltrate or consolidation suggesting the presence of community acquired pneumonia. A portable ultrasound machine with a convex probe, that will be provided to the general practitioner by the study, will be used.~The lung ultrasound will be done following international evidence-based recommendations for point-of-care lung ultrasound using the basic eight-region sonographic technique and the criteria for positive scan and positive examination for the diagnosis of pneumonia .

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Procalcitonin
Description: Procalcitonin will be measured using a rapid point-of-care test

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: A venous blood sample (17.5 mL) will be collected. Whole blood and plasma will be stored at - 80°C. Further analysis will be performed in order to identify novel biomarkers and gene transcription patterns that could predict the necessity of antibiotic prescription or the severity of disease.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: A venous blood sample (17.5 mL) will be collected. Whole blood and plasma will be stored at - 80°C. Further analysis will be performed in order to identify novel biomarkers and gene transcription patterns that could predict the necessity of antibiotic prescription or the severity of disease.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Naso-pharyngeal swab and sputum culture
Description: A pooled nasal swab will be performed and sputum will be collected. Samples will be stored at -80°C. Further analysis of the naso-pharyngeal swab and cultures of sputum will be performed to identify by molecular techniques pathogens implicated in the clinical presentation.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Naso-pharyngeal swab and sputum culture
Description: A pooled nasal swab will be performed and sputum will be collected. Samples will be stored at -80°C. Further analysis of the naso-pharyngeal swab and cultures of sputum will be performed to identify by molecular techniques pathogens implicated in the clinical presentation.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Naso-pharyngeal swab and sputum culture
Description: A pooled nasal swab will be performed and sputum will be collected. Samples will be stored at -80°C. Further analysis of the naso-pharyngeal swab and cultures of sputum will be performed to identify by molecular techniques pathogens implicated in the clinical presentation.
Study: NCT03990636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metil 5-aminolevulinate
Description: Scrubbing lip vermillion and applying the medication or placebo that is activated (or not, in case of placebo) with red light.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metil 5-aminolevulinate
Description: Scrubbing lip vermillion and applying the medication or placebo that is activated (or not, in case of placebo) with red light.
Study: NCT03672799

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation Planning Consult (RPC)
Description: Participants allocated to RPC will receive a 1 hour consultation with the Rehabilitation Consult and second consultation over the next 12 weeks as needed.~Participants will be assessed at three time points, 1) Baseline assessment, 1 week prior to RPC, 2) post-intervention assessment, 1 week after RPC, and 3) follow-up assessment, 13 weeks after RPC.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation Planning Consult (RPC)
Description: Participants allocated to RPC will receive a 1 hour consultation with the Rehabilitation Consult and second consultation over the next 12 weeks as needed.~Participants will be assessed at three time points, 1) Baseline assessment, 1 week prior to RPC, 2) post-intervention assessment, 1 week after RPC, and 3) follow-up assessment, 13 weeks after RPC.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wait list control (WLC)
Description: Participants who are allocated to WLC will complete a 12 week waiting period. At the end of the waiting period, participants will crossover to the RPC group.~Participants will be assessed at four time points, 1) Baseline assessment, 1 week prior to waiting period, 2) post-waiting period assessment, 1 week after waiting period, 3) post-intervention assessment, 1 week after RPC, and 4) follow-up assessment,13 weeks after RPC.
Study: NCT02864823

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perichondrium Autografts
Description: Perichondrium tissue was harvested from the patient's ear cartilage and transplanted to reconstruct the scleral defect.
Study: NCT01410864

Intervention type: DEVICE
Intervention: DuraSeal Exact Spine Sealant System
Description: DuraSeal Exact Spine Sealant System will be administered to those eligible patients, to treat a dural opening.

Intervention type: OTHER
Intervention: Control
Description: Devices or drugs used to seal the dura (other than DuraSeal)
Study: NCT02118259

Intervention type: OTHER
Group type: OTHER
Intervention: Before-after study
Description: The before-after study is composed of a first observational phase followed by a proactive phase, and then finally by a second observational phase.~The first observational phase corresponds to retrospective data-collecting for the information necessary for calculating the baseline ADE geriatric risk score.~The proactive phase corresponds to a multidisciplinary review of drug prescriptions (especially long-term drugs) for all included patients in the residence.~During the second observational phase, the same data as in the first observational phase will be collected a second time.
Study: NCT01146028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tizanidine
Description: Tizanidine HCl Tablets 4 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tizanidine
Description: Tizanidine HCl Tablets 4 mg
Study: NCT02412254

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best practices hearing rehabilitative treatment
Description: Intervention comprises hearing needs assessment, counselling, sensory management with amplification devices, and rehabilitative training.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Successful aging intervention
Description: One-on-one education sessions on healthy aging topics (cancer screening, smoking cessation, etc.) between a trainer and participant
Study: NCT03299725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colloidal bismuth sub-citrate
Description: colloidal bismuth sub-citrate administered as an adjunctive therapy in combination with esomeprazole, amoxicillin and metronidazole
Study: NCT03385551

Intervention type: DRUG
Intervention: Estradiol
Description: Estradiol or Promestriene depending on the arm
Study: NCT02450422

Intervention type: OTHER
Intervention: Flow cytometry (FCM)
Description: Use FCM to test PBMCs/CTCs from volunteers/patients.

Intervention type: OTHER
Intervention: Flow cytometry (FCM)
Description: Use FCM to test PBMCs/CTCs from volunteers/patients.

Intervention type: OTHER
Intervention: Flow cytometry (FCM)
Description: Use FCM to test PBMCs/CTCs from volunteers/patients.

Intervention type: OTHER
Intervention: Flow cytometry (FCM)
Description: Use FCM to test PBMCs/CTCs from volunteers/patients.

Intervention type: OTHER
Intervention: RT-PCR
Description: Use RT-PCR to test PBMCs/CTCs from volunteers/patients.

Intervention type: OTHER
Intervention: RT-PCR
Description: Use RT-PCR to test PBMCs/CTCs from volunteers/patients.

Intervention type: OTHER
Intervention: RT-PCR
Description: Use RT-PCR to test PBMCs/CTCs from volunteers/patients.

Intervention type: OTHER
Intervention: RT-PCR
Description: Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
Study: NCT00869973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Aprepitant 80 mg orally: 24 hours after chemotherapy on day 2 and then at 8 am on day 3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: dexamethasone 4 mg orally: 24 hours after chemotherapy and at 8 pm on day 2, then at 8 am and 8 pm on day 3
Study: NCT01283022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVI 200
Description: Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
Study: NCT01538394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Varenicline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patches

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (nicotine patches)
Study: NCT03503734

Intervention type: BEHAVIORAL
Intervention: Integrated headache care
Description: The treatment can be realized on an inpatient, outpatient and/or day care basis, according to the severity level of illness and comorbidities.~The inpatient treatment takes place at the Department of Internal and Integrative Medicine. The stay is slated for 14 days.~Day care can follow the inpatient stay or can be applied as sole therapy. As part of the standard care provided at the Department for Internal and Integrative Medicine, it occurs at a semi-residential clinic for 6 hours once a week over a total of 10 weeks.~The outpatient treatment is delivered in the Department's outpatient ward. It consists of acupuncture, cupping, hydrotherapy and massages as well as nutritional counseling. The patients can additionally be offered one-to-one mind-body-medicine interventions.
Study: NCT01522131

Intervention type: PROCEDURE
Group type: OTHER
Intervention: bioresorbable membrane alonewill be used for regeneration of the periodontium(control)
Description: bioresorbable membrane with laser will be used for regeneration of the periodontium(test)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bioresorbable membrane alonewill be used for regeneration of the periodontium(control)
Description: bioresorbable membrane with laser will be used for regeneration of the periodontium(test)
Study: NCT03103685

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clopidogrel
Description: The patient s in experimental arm will not be ask to stop P2Y12 inhibitor such as Clopidogrel, Prasugrel or Ticagrelor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: The patient s in experimental arm will not be ask to stop P2Y12 inhibitor such as Clopidogrel, Prasugrel or Ticagrelor
Study: NCT02063581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipatasertib (Capsule)
Description: Orally administered single dose of Ipatasertib formulated as a capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipatasertib (Capsule)
Description: Orally administered single dose of Ipatasertib formulated as a capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipatasertib (Tablet)
Description: Orally administered single dose of Ipatasertib formulated as a tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipatasertib (Tablet)
Description: Orally administered single dose of Ipatasertib formulated as a tablet.
Study: NCT00607464

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polyethylene occlusive skin wrap
Description: Polyethylene occlusive skin wrap applied immediately after birth and removed after the infant has been admitted to a stable thermoneutral environment
Study: NCT02612506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepalatide
Description: There are seven cohorts as follows 0.21mg, 0.525mg, 2.1mg, 4.2mg, 6.3mg, 8.4mg and 10.5mg. Dose of 0.21mg is a pilot trial with no placebo. At each dose level, healthy volunteers will be received treatment drug by abdominal subcutaneous injection at the first day and monitored for 8 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: There are six cohorts as follows 0.525mg, 2.1mg, 4.2mg, 6.3mg, 8.4mg and 10.5mg. At each dose level, healthy volunteers will be received control drug by abdominal subcutaneous injection at the first day and monitored for 8 days.
Study: NCT06376305

Intervention type: DEVICE
Group type: OTHER
Intervention: EndoBarrier
Description: During screening visit, a brief history, examination, blood tests and 2 sleep studies within a gap of 1 week will be performed. Then, there will be an assessment by gastroenterologist for EndoBarrier insertion. EndoBarrier will be inserted endoscopically as a day case procedure after the midnight fast, under general anaesthesia. Following the EndoBarrier insertion, there will be 3 monthly trial visits until one year where the following assessments will be performed - brief interview, observations, blood tests, urine test, dietitian review, compliance check with CPAP and quality of life questionnaire.~At the end of one year, EndoBarrier will be removed endoscopically again as a day case procedure under general anaesthesia. Then, there will be follow up trial visits every 3 months up to one year where there will be clinical assessments, sleep studies, blood tests, urine test, dietitian, compliance check and quality of life questionnaires.
Study: NCT04045847

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD147-CART
Description: Three doses of CD147-CART cells were injection to intracavity by Ommaya Reservoir.
Study: NCT03510429

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Postoperative Nutritional Supplement
Description: Postoperative Nutritional Supplement (newly developed ketogenic drink: NDKD)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine post-op care
Description: Routine post-operative care